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Big Fat Wedding
ssociation of Adiponectin
ith Coronary Vascular Lesions*
andeep Bajaj, MD,†
ri Ben-Yehuda, MD, FACC‡
alveston, Texas; and San Diego, California
ncreasing obesity rates and a sedentary lifestyle worldwide
ave led to a marked increase in rates of type 2 diabetes as
ell as the metabolic syndrome (MetS), which is character-
zed by a clustering of cardiovascular risk factors (1). The
wo main etiologic factors for the MetS, obesity and insulin
esistance, often are interrelated and concomitantly present.
espite recent claims that the cardiovascular risk associated
ith the MetS is simply the additive risk of the individual
isk factors identified in patients with MetS, the concept is
till clinically useful given the clustering of risk factors and
he underlying etiologic factors of insulin resistance and
besity (2).
See page 1155
The realization that adiposity and particularly visceral
diposity (3) are potent risk factors for the development of
ype 2 diabetes has focused renewed attention on the role of
he adipocyte in the development of both diabetes and
ardiovascular disease. Once regarded as a relatively inert
torage depot for fat, adipose tissue is now recognized as an
mportant endocrine organ. The adipocyte, in response to
pecific extracellular stimuli or changes in metabolic condi-
ions, releases a host of hormones and cytokines. These
ecreted proteins, which include tumor necrosis factor-
lpha, leptin, resistin, adiponectin, and others, perform
iverse functions. They have been collectively referred to as
dipokines and are postulated to play an important role in
he pathogenesis of insulin resistance, as well as the often-
ssociated hypertension, disorders of coagulation, and dys-
ipidemia. An associated low-grade inflammatory state also
s present in the MetS and diabetes, and may be mediated
y adipokines (4).
The most abundant adipokine produced by visceral fat
ells is adiponectin, an adipose tissue-specific 30-kDa pro-
ein, which is cleaved proteolytically to release a C-terminal
lobular domain (5,6). Insulin resistance, type 2 diabetes,
nd coronary artery disease are characterized by decreased
irculating concentrations of adiponectin (7–9). Although
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.d
From the †University of Texas, Galveston, Texas; and the ‡University of Califor-
ia, San Diego, California.diponectin is produced by adipose cells, blood levels
ctually are inversely proportional to visceral adiposity (10).
A strong relationship has been demonstrated between
lasma adiponectin levels and both hepatic and peripheral
issue insulin sensitivity in patients with type 2 diabetes (7).
ne of the primary effects of adiponectin is to increase fatty
cid oxidation in muscle, leading to a decrease in intracel-
ular fatty acid metabolites, i.e., fatty acyl coenzyme A,
iacylglycerol, ceramides, and enhanced insulin signal trans-
uction. Treatment with a thiazolidinedione (TZD) in-
reases circulating adiponectin concentrations by almost
-fold in patients with type 2 diabetes (7). Exercise has also
een shown to increase adiponectin levels (8). Circulating
diponectin exists in at least two forms in serum, as a
examer referred to as a low molecular weight (LMW)
omplex and as a high molecular weight (HMW) complex
onsisting of 12 to 18 subunits (9). The ratio between these
wo oligomeric forms (HMW to LMW) is critical in deter-
ining TZD-mediated increase in insulin sensitivity (11).
Adiponectin has been shown to have antiatherogenic and
nti-inflammatory effects in rodents (12). In genetic studies,
strong linkage is observed between the chromosomal
egion encompassing the adiponectin gene (APM1) and risk
actors for cardiovascular disease (13). The I164T mutation
n the adiponectin gene also has been shown to be a
ommon genetic polymorphism associated with the meta-
olic syndrome and coronary artery disease (CAD) in the
apanese population (14). Hypoadiponectinemia is closely
ssociated with increased plasma levels of inflammatory
arkers such as C-reactive protein (15). Adiponectin in-
ibits tumor necrosis factor-alpha–induced activation of
uclear factor-kappa-B-dependent proinflammatory path-
ays, expression of endothelial adhesion molecules,
acrophage-to-foam cell transformation, lipid accumula-
ion in macrophages, and smooth muscle cell proliferation
16,17). Furthermore, adiponectin has been shown to pre-
ent angiotensin II-induced human endothelial cell apopto-
is (18). It remains to be investigated whether low plasma
diponectin levels contribute directly or indirectly (by ag-
ravating the individual components of the metabolic syn-
rome, including insulin resistance) to accelerated athero-
clerosis in patients with metabolic syndrome.
Studies have provided evidence for a link between hypo-
diponectinemia and impaired nitric oxide generation. Di-
inished brachial arterial endothelium-dependent vasodila-
ation has been associated with reduced adiponectin levels in
ubjects with type 2 diabetes and with hypertension (19).
nimal models of adiponectin deficiency are characterized
y severe neointimal hyperplasia that can be reversed with
diponectin repletion (12). Recent in vitro studies (20) using
ovine aortic endothelial cells have shown that adiponectin
timulates nitric oxide (NO) production by increasing en-
othelial nitric oxide synthase (eNOS) enzyme activity and
NOS expression via a phophatidylinositol 3-kinase–
ependent pathway that causes phosphorylation/activation
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Editorial Comment September 19, 2006:1163–5f eNOS at Ser1179 by AMP-activated protein kinase. In a
at model of NO synthesis deficiency produced by L-NAME,
lasma adiponectin concentration and adiponectin messenger
NA levels in the aorta were noted to be reduced (21).
reatment using TZD increased fat adiponectin messenger
NA levels and normalized the plasma adiponectin concen-
ration in association with an increase in NO synthesis in
rterial tissue. These results provide evidence that, in
odents in vivo, adiponectin is an important regulator of NO
ynthesis and could explain some of the observed vasopro-
ective properties of adiponectin.
The identification of two adiponectin receptors in mice
epresents a significant breakthrough in our understanding
f the mechanism of adiponectin action (22). AdipoR1 is
bundantly expressed in skeletal muscle, whereas AdipoR2
s predominantly expressed in the liver. AdipoR1 and
dipoR2 serve as receptors for globular and full-length
diponectin and mediate stimulation of AMP-activated
rotein kinase, fatty acid oxidation, and glucose uptake.
ore recently, the expression of adipoR1 and adipoR2 also
as been demonstrated in human monocytes and macro-
hages (23). Skeletal muscle adiponectin receptors AdipoR1
nd AdipoR2 expression levels are strongly related to periph-
ral (muscle) insulin sensitivity in humans in vivo (24).
In this issue of the Journal, Otsuka et al. (25) demonstrate
hat low plasma adiponectin levels are associated with
omplexity of angiographic coronary lesions in men both in
table CAD and in acute coronary syndrome (ACS). Given
he association of plaque complexity with plaque vulnera-
ility, they suggest that hypoadiponectinemia may contrib-
te to coronary plaque vulnerability. In addition, they
emonstrate that patients with ACS have lower plasma
diponectin concentration than patients with stable coro-
ary artery disease. Their findings are important given the
igher prevalence of diabetes and impaired glucose tolerance
n patients with ACS (26) and suggest that hypoadi-
onectinemia may be an important link between type 2
iabetes, CAD, enhanced plaque vulnerability, and ACS.
n increase in plasma adiponectin levels after treatment
ith TZD may be particularly valuable in enhancing coro-
ary plaque stability and preventing ACS in patients with
ype 2 diabetes. The recent results of the PROactive
PROspective pioglitAzone Clinical Trial In macroVascular
vents) trial (27), demonstrating a reduction in myocardial
nfarction rate over the course of 2 years of treatment with
he TZD pioglitazone, may be the first evidence that
harmacologic intervention that increases adiponectin levels
among other interrelated effects of the TZDs) may be
linically relevant.
The complexity of atherosclerosis and plaque instability
ndoubtedly involves multiple interrelated risk factors and
ediators. Given the relatively small size of the study by
tsuka et al. (25), the clinical utility of adiponectin as a
iomarker remains to be determined in much larger studies.
hether adiponectin provides incremental predictive valueo established risk factors such as cholesterol/high-density
1ipoprotein and the diagnosis of metabolic syndrome or
iabetes itself remains to be determined in larger prospective
tudies. Moreover, whether adiponectin’s role in atheroscle-
osis is direct or whether its effects are mediated through
ther interrelated metabolic players such as high-density
ipoprotein cholesterol also remains to be fully elucidated.
nd although the routine use of adiponectin as a biomarker
n medicine is still premature, it remains an important target
or study, not only as a potential marker of disease but also
s a target for pharmacologic intervention.
eprint requests and correspondence: Dr. Ori Ben-Yehuda,
ivision of Cardiology, University of California, San Diego, 200
est Arbor Drive, San Diego, California 92103-8411. E-mail:
benyehuda@ucsd.edu.
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